Free Trial
NASDAQ:OMCL

Omnicell Q3 2025 Earnings Report

Omnicell logo
$30.95 +0.97 (+3.24%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$30.94 -0.02 (-0.05%)
As of 10/3/2025 05:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omnicell EPS Results

Actual EPS
N/A
Consensus EPS
$0.36
Beat/Miss
N/A
One Year Ago EPS
N/A

Omnicell Revenue Results

Actual Revenue
N/A
Expected Revenue
$295.59 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Omnicell Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Omnicell Earnings Headlines

Analysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $46.71
Why BRICS, BlackRock, and Singapore Are All Aligned
This Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top Fall 2025 pick sits at the center of it all...tc pixel
Craig-Hallum Reaffirms Their Buy Rating on Omnicell (OMCL)
See More Omnicell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Omnicell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Omnicell and other key companies, straight to your email.

About Omnicell

Omnicell (NASDAQ:OMCL) is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum. The company completed its initial public offering on the Nasdaq under the ticker OMCL and has invested heavily in research and development, focusing on robotics, bar-coding and cloud-based data services. Omnicell’s continuous product enhancements reflect its commitment to automating complex pharmacy processes and driving digital transformation in healthcare.

Omnicell serves a global customer base that includes acute care hospitals, health systems, retail pharmacies and long-term care facilities. While its primary market remains North America, the company maintains operations and support centers throughout Europe and the Asia-Pacific region. This international footprint enables Omnicell to tailor solutions to diverse regulatory environments and to partner with healthcare organizations worldwide in improving medication safety and operational efficiency.

Under the leadership of co-founder and Chief Executive Officer Randall A. Lipps, Omnicell has expanded its technology suite to address emerging needs such as antimicrobial stewardship, telepharmacy and remote drug distribution. The company’s executive team continues to prioritize innovation, seeking to integrate advanced analytics and artificial intelligence into its platforms to help clinicians make more informed decisions and enhance overall patient care.

View Omnicell Profile

More Earnings Resources from MarketBeat